Suchergebnisse - "Hasegawa, Tetsuya"

PubPharm (12)

1

Role of human flavin-containing monooxygenase (FMO) 5 in the metabolism of nabumetone : Baeyer-Villiger oxidation in the activation of the intermediate metabolite, 3-hydroxy nabumetone, to the active metabolite, 6-methoxy-2-naphthylacetic acid in vitro

enthalten in: Xenobiotica; the fate of foreign compounds in biological systems | 2021

von Matsumoto, K. | Hasegawa, T. | Ohara, K. | +3

2

Role of human flavin-containing monooxygenase (FMO) 5 in the metabolism of nabumetone: Baeyer–Villiger oxidation in the activation of the intermediate metabolite, 3-hydroxy nabumetone, to the active metabolite, 6-methoxy-2-naphthylacetic acidin vitro

enthalten in: Xenobiotica | 2021

von Matsumoto, K. | Hasegawa, T. | Ohara, K. | +3

3

A metabolic pathway for the prodrug nabumetone to the pharmacologically active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA) by non-cytochrome P450 enzymes

enthalten in: Xenobiotica; the fate of foreign compounds in biological systems | 2020

von Matsumoto, K. | Hasegawa, T. | Ohara, K. | +5

4

A metabolic pathway for the prodrug nabumetone to the pharmacologically active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA) by non-cytochrome P450 enzymes

enthalten in: Xenobiotica | 2020

von Matsumoto, K. | Hasegawa, T. | Ohara, K. | +5

5

Roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone

enthalten in: Journal of pharmaceutical investigation | 2020

von Matsumoto, K. | Hasegawa, T. | Ohara, K. | +2

6

Roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone

enthalten in: Journal of pharmaceutical investigation | 2019

von Matsumoto, K. | Hasegawa, T. | Ohara, K. | +2

7

Determination of the Absolute Configuration of the Nabumetone Metabolite 4-(6-Methoxy-2-naphthyl)butan-2-ol Using the Chiral Derivatizing Agent, 1-Fluoroindan-1-carboxylic Acid

enthalten in: Chemical & pharmaceutical bulletin | 2019

von Kamei, T. | Kimura, Y. | Koyanagi, J. | +4

8

Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions : exploratory prediction using inhibitors and substrates as marker probes

enthalten in: European journal of drug metabolism and pharmacokinetics | 2015

von Matsumoto, K. | Hasegawa, T. | Koyanagi, J. | +3

9

Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes

enthalten in: European journal of drug metabolism and pharmacokinetics | 2014

von Matsumoto, K. | Hasegawa, T. | Kamei, T. | +4

10

Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes

enthalten in: European journal of drug metabolism and pharmacokinetics | 2014

von Matsumoto, K. | Hasegawa, T. | Kamei, T. | +4